ARS Pharmaceuticals, Inc. SPRY 深 沪
等待开盘 08-20 09:30:00 美东时间
6.38
+0.080
+1.27%
华盛通- 最 高6.58
- 今 开6.42
- 成交量 121.24万股
- 最 低 6.35
- 昨 收 6.30
- 总市值 6.34亿
- 52周最高 13.15
- 市盈率 静 --
- 换手率 1.22%
- 52周最低 4.9102
- 委 比 31.06%
- 总股本 9944.73万
- 历史最高 63.41
- 量 比 0.47
- 振 幅 3.65%
- 历史最低 2.55
- 每 手 1
- 风险率 1.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ARS Pharmaceuticals (SPRY) 2026财年第二季度业绩电话会议：neffy市场份额增长与成本重置
ARS Pharmaceuticals 2026年第二季度业绩电话会议：随着neffy获得更多市场份额，营收达到3370万美元，同时管理层削减成本，并旨在2027年实现现金收支平衡。
08-14 08:40
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results.
08-14 04:45
财报速睇 | ARS Pharmaceuticals, Inc. 2026财年Q2营收0.34亿美元，同比增长114.2%；归母净利润亏损0.62亿美元，同比亏损扩大38.9%
华盛资讯8月14日讯，ARS Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收0.34亿美元，同比增长114.2%，归母净利润亏损0.62亿美元，同比亏损扩大38.9%。
08-14 04:37
财报速睇 | ARS Pharmaceuticals, Inc. 2026财年Q2营收0.34亿美元，同比增长112.5%；归母净利润亏损0.62亿美元，同比亏损扩大37.8%
华盛资讯8月14日讯，ARS Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收0.34亿美元，同比增长112.5%，归母净利润亏损0.62亿美元，同比亏损扩大37.8%。
08-14 04:24
ARS Pharmaceuticals Announces Key Executive Leadership Departures
An update from ARS Pharmaceuticals ( ($SPRY) ) is now available. On July 15, 20...
07-18 05:36
Can ARS Pharma's New CEO Unlock Neffy's Potential?
On Tuesday, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) announced a leadership transition. Co-founder and CEO Richard Lowenthal stepped down as an employee and officer, effective July 6, 2026. The board appointed Donn Casale, the company’s current president, as CEO and a director, effective July 7, 2026....
07-10 01:37
ARS Pharmaceuticals appoints new CEO
ARS Pharmaceuticals (SPRY) appointed Donn Casale as chief executive officer and director, effective July 7, 2026, succeeding co-founder Richard Lowenthal. Richard Lowenthal stepped down as an employee...
07-08 04:35
ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective July 7
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to anaphylaxis, today announced a CEO succession, in which co-founder and CEO Richard Lowenthal will no lon...
07-08 04:31
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 2% on Thursday. Shares of H.B. Fuller Company (NYSE:FUL) fell sharply in pre-market trading following second-quarter results. H.B. Fuller posted upbeat earnings for the second quarter and raised its FY2026 ear...
06-25 20:08
